Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 510.51M | 535.18M | 53.76M | 67.42M | 102.99M | 48.90M |
Gross Profit | 484.00M | 429.35M | -70.61M | -116.57M | -135.21M | 34.73M |
EBITDA | 238.59M | 209.69M | -234.09M | -209.39M | -386.49M | -123.09M |
Net Income | 193.64M | 162.19M | -260.17M | -249.03M | -411.72M | -129.07M |
Balance Sheet | ||||||
Total Assets | 688.88M | 802.83M | 788.25M | 860.47M | 1.16B | 1.51B |
Cash, Cash Equivalents and Short-Term Investments | 395.81M | 485.37M | 405.11M | 500.28M | 816.11M | 1.33B |
Total Debt | 36.03M | 38.97M | 41.82M | 42.09M | 28.89M | 30.09M |
Total Liabilities | 102.51M | 106.22M | 271.31M | 327.22M | 469.77M | 800.01M |
Stockholders Equity | 586.37M | 696.61M | 516.94M | 533.25M | 688.48M | 711.35M |
Cash Flow | ||||||
Free Cash Flow | 196.15M | 83.41M | -323.09M | -379.40M | -861.03M | 475.05M |
Operating Cash Flow | 204.08M | 101.85M | -267.89M | -286.18M | -733.13M | 522.40M |
Investing Cash Flow | -7.93M | -18.44M | -55.20M | -93.50M | -127.90M | -45.27M |
Financing Cash Flow | -5.39M | -5.11M | 230.89M | 63.17M | 344.96M | 819.83M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $1.21B | 5.90 | 34.46% | ― | 799.36% | ― | |
68 Neutral | $1.84B | 39.68 | 18.17% | ― | 1218.82% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.23B | ― | -113.22% | ― | 2133.71% | -15.38% | |
46 Neutral | $1.67B | ― | -15.64% | ― | -0.54% | -6.28% | |
46 Neutral | $1.09B | ― | -26.25% | ― | ― | 79.90% | |
36 Underperform | $1.27B | ― | -25.26% | ― | ― | -3.53% |
CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline in revenue compared to the previous year. The company reported a net loss for the period, highlighting challenges in its financial performance. The financial results indicate a decrease in cash and cash equivalents, reflecting operational difficulties and potential impacts on stakeholders and market positioning.
On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive $740 million and royalties on U.S. vaccine sales. Additionally, CureVac will grant a non-exclusive license to BioNTech and Pfizer for mRNA-based products, which will expand globally upon BioNTech’s acquisition of CureVac. This resolution is expected to streamline CureVac’s operations and strengthen its industry position.